TSXV:TRL.H - Post by User
Post by
LTOWNERon Jun 11, 2014 9:03am
263 Views
Post# 22648519
Orals are Not a Shoe-In
Orals are Not a Shoe-InClarus hasz had some problems with the FDA and experienced 4 cardiac incidences in one of its studies. Also the average testosteone level achieved post treatment with their product in relatively high. Remember the highest morbidity and mortality from all causes is in men with low T followed by men with high T. Natesto provides a moderate normal level - perhaps why men on Natesto felt better than on other T products. That and the IN delivery that more closely mimics natural T delivery.
I would not be surprised to see Clarus get delayed, or perhaps that is wishful thinking, but the FDA is very careful with TRT now.